Clinical characteristics of obese patients with adult-onset Still's disease. Data from a large multicentre cohort

Joint Bone Spine. 2023 Sep;90(5):105576. doi: 10.1016/j.jbspin.2023.105576. Epub 2023 Apr 18.

Abstract

Objectives: To evaluate the impact of obesity in patients with adult-onset Still's disease (AOSD) and to assess their clinical characteristics and disease outcomes.

Methods: The clinical features of AOSD patients with a body mass index (BMI)≥30 were assessed among those included in the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort.

Results: Out of 139 AOSD patients, who had BMI registered in our database, 26 (18.7%) had a BMI≥30. A lower rate of sore throat (P<0.05), pericarditis (P<0.05), and pleuritis (P<0.05) was shown in obese patients. Additionally, obese patients showed higher values of C-reactive protein (CRP) (P<0.05) and ferritin (P<0.05) than others. Furthermore, obese patients were characterised by biologic disease-modifying antirheumatic drug (bDMARD) failure in subsequent follow-up (P<0.05). They also presented higher rate of comorbidity than non-obese patients (P<0.05). Finally, obesity predicted the presence of a chronic disease course in both univariate (HR: 1.72, 95%CI: 1.03-2.51, P<0.05) and multivariate analyses (HR: 1.85, 95%CI: 1.45-2.89, P<0.05). Obesity was also a significant predictor of bDMARD failure in AOSD patients in both univariate (HR: 3.03, 95%CI: 1.42-6.45, P<0.01) and multivariate analyses (HR: 3.59, 95%CI: 1.55-8.27, P<0.01).

Conclusion: Obese patients at the time of diagnosis of the disease were characterised by a lower prevalence of sore throat, serositis, as well as by higher values of CRP and ferritin. Obesity was also a predictive factor for a chronic disease course and bDMARD failure, thus highlighting a subset of patients with AOSD to be carefully managed.

Keywords: Adult-onset Still's disease; Body mass index; Obesity.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Antirheumatic Agents* / therapeutic use
  • C-Reactive Protein / metabolism
  • Disease Progression
  • Ferritins
  • Humans
  • Obesity / complications
  • Obesity / epidemiology
  • Still's Disease, Adult-Onset* / complications
  • Still's Disease, Adult-Onset* / diagnosis
  • Still's Disease, Adult-Onset* / epidemiology

Substances

  • Antirheumatic Agents
  • C-Reactive Protein
  • Ferritins